236 related articles for article (PubMed ID: 34731509)
1. Review on natural killer/T-cell lymphoma.
He X; Gao Y; Li Z; Huang H
Hematol Oncol; 2023 Apr; 41(2):221-229. PubMed ID: 34731509
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
Tse E; Kwong YL
Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
[TBL] [Abstract][Full Text] [Related]
3. How we treat NK/T-cell lymphomas.
Tse E; Zhao WL; Xiong J; Kwong YL
J Hematol Oncol; 2022 Jun; 15(1):74. PubMed ID: 35659326
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Asano N; Kato S; Nakamura S
Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
[TBL] [Abstract][Full Text] [Related]
5. Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).
Haverkos BM; Coleman C; Gru AA; Pan Z; Brammer J; Rochford R; Mishra A; Oakes CC; Baiocchi RA; Freud AG; Porcu P
Discov Med; 2017 Mar; 23(126):189-199. PubMed ID: 28472613
[TBL] [Abstract][Full Text] [Related]
6. The diagnosis and management of NK/T-cell lymphomas.
Tse E; Kwong YL
J Hematol Oncol; 2017 Apr; 10(1):85. PubMed ID: 28410601
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of natural killer-cell malignancies.
Ishida F; Kwong YL
Expert Rev Hematol; 2010 Oct; 3(5):593-602. PubMed ID: 21083476
[TBL] [Abstract][Full Text] [Related]
8. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
[TBL] [Abstract][Full Text] [Related]
9. High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
de Pádua Covas Lage LA; Machado PPF; Reichert CO; Miranda E; Culler HF; da Siqueira SAC; de Oliveira Costa R; Miyashiro DR; Sanches JA; Rocha V; Chiattone CS; Pereira J
Sci Rep; 2022 Nov; 12(1):20557. PubMed ID: 36446856
[TBL] [Abstract][Full Text] [Related]
10. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
11. Extranodal natural killer/T-cell lymphoma with hepatosplenic involvement: a retrospective study of a consecutive 14-year case series.
Zhang YH; Li Z; Zhao S; Zhang WY; Liu QL; Liu WP; Gao LM
Ann Hematol; 2023 Oct; 102(10):2803-2813. PubMed ID: 37434096
[TBL] [Abstract][Full Text] [Related]
12. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Yamaguchi M; Suzuki R; Oguchi M
Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
[TBL] [Abstract][Full Text] [Related]
13. Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.
Liu YC; Lin TA; Wang HY; Ko PS; Liu CJ; Hsiao LT; Chien SH; Gau JP
J Med Case Rep; 2020 Mar; 14(1):43. PubMed ID: 32183896
[TBL] [Abstract][Full Text] [Related]
14. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
[TBL] [Abstract][Full Text] [Related]
15. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.
Tsuyama N; Asaka R; Dobashi A; Baba S; Mishima Y; Ueda K; Oguchi M; Tsuji H; Hatake K; Takeuchi K
Hematol Oncol; 2018 Feb; 36(1):328-335. PubMed ID: 28695659
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features.
Jeon YK; Kim JH; Sung JY; Han JH; Ko YH;
Hum Pathol; 2015 Jul; 46(7):981-90. PubMed ID: 25907865
[TBL] [Abstract][Full Text] [Related]
19. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
20. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
